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Tetra-O-acetate haloacetamido carbohydrate analogs (Tet-OAHCs) are novel alkylating agents that
appear to have alkylating activity at the plasma membrane, speciﬁcity against neoplastic cells, and may
potentiate host leukocyte inﬂux. This study sought to characterize the chemical attributes and in vivo
activity of Tet-OAHCs. Four Tet-OAHCs were assessed for their partition coefﬁcient and alkylating activity
to determine cellular environments where adduct formationwould be favorable. In vitro, IC50 values of all
four Tet-OAHCs were determined against Ehrlich ascites murine carcinoma, as well as two leukemias
(U937 human monocytic leukemia and L1210 murine lymphoid leukemia) to assess their cytotoxicity in
multiple neoplastic cell lines. In vivo, B6D2F1 and CD2F1 mice were challenged i.p. with Ehrlich ascites
carcinoma prior to, or after being treated with a single dose of one of the analogs. Finally, a quantitative
comparison of host leukocyte inﬂux between Tet-OAHCs and other alkylating agents was performed to
conﬁrm previous in vivo observations that the tetra-O-acetate carbohydrate moiety is important for
inducing a host leukocyte response in murine models.
The results can be summarized as follows: 1) Tet-OAHCs appear to demonstrate high alkylating ac-
tivity in amphiphilic environments. 2) All four congeners have comparable in vitro cytotoxicities against
the neoplastic cell lines examined. 3) The analogs demonstrate marked in vivo activity in both B6D2F1
and CD2F1 mice challenged with a lethal dose of Ehrlich ascites carcinoma, and frequently produce long
term survival at 60 days, which is not observed in simple halo derivatives or two currently approved
antineoplastic agents (daunorubicin and mechlorethamine). These effects are observed when the agents
are administered either before or after the tumor challenge. 4) The carbohydrate moiety appears to be
important for potentiating host leukocyte inﬂux, as Tet-OAHCs, but not other alkylating agents
demonstrated such activity in vivo.
© 2015 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alkylating agents have been a mainstay in cancer chemotherapy
due to their ability to readily interfere with the rapid mitotic pro-
gression of malignant cells. These agents are known for alkylating
nucleophilic DNA (often at N-7 in guanine bases), prompting the
formation of DNA adducts, crosslinking in the presence of difunc-
tional agents, and ultimately apoptosis [1,2]. Although alkylating
agents and related platinating agents have been vital for the success
of current chemotherapeutic protocols, there are notable limita-
tions. Their crosslinking capability is considerably reduced in thei).
Masson SAS. This is an open accesspresence of the DNA-repair enzyme O-6-methylguanine-DNA
methyltransferase (MGMT) [1,3,4]. Alkylating-like agents also face a
similar problem of rapid DNA repair as the propensity of nucleotide
excision repair (NER) is ever-present in a substantial variety of
cancers [2]. Therefore, the ability of malignant cells to repair
damaged DNA is an apparent constraint on the efﬁcacy of currently
approved alkylating agents.
Although DNA has been the nucleophilic target of all clinically
approved alkylating agents, it may also be possible to alkylate the
plasma membrane of malignant cells to exert antineoplastic ac-
tivity. It has been known for quite some time that plasma mem-
brane proteins exposed on the cell surface have important
biological functions, such as cell signaling, ion transport, and
cellecell and cell-matrix adhesion interactions [5e8]. Due to recent
advances in genomic, transcriptomic, and proteomic analysis, it hasarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. Characterization of tetra-O-acetate haloacetamido carbohydrate analogs. A)
General structure of haloacetamides. Reactivity at the CH2X group is controlled by the
electron withdrawing or donating power of the R group, and the corresponding pKa of
the parent amine. The hydrogen bond donating and accepting properties of the amide
nitrogen allow the reactivity to be modulated by the dielectric constant of the in vivo
environment. B) Basic structure of tetra-O-acetate haloacetamido carbohydrates (Tet-
OAHCs).
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brane proteins is altered in malignant cells [5,6,9]. Such protein
alterations often confer metastatic properties, creating a target for
monoclonal antibodies and other forms of immunotherapy. While
these approaches target speciﬁc aberrancies on the cell surface,
alkylating agents would react nonspeciﬁcally with functional
groups on the exterior of the plasma membrane, circumventing the
need for a designated target to be present.
Although cell-surface biochemistry is a suitable target for
chemotherapeutic investigation, the characteristics of agents that
affect exterior plasmamembrane signaling to produce therapeutic
beneﬁt are less inherent. A logical target may be cell surface gly-
coconjugates, as they are pivotal in surface membrane biochem-
istry, and altering such signaling through alkylation could have
considerable antineoplastic potential. Carbohydrates are involved
in the adhesion of cells to substrates, as well as their adherence to
each other. They have been shown to change in accessibility as a
function of the cell cycle, and have been indicated to play a pivotal
role in cell differentiation [9,10]. Further, cell surface carbohy-
drates have a profound inﬂuence on host immune response.
Lectin-like carbohydrate binding sites are integral for the inter-
action of cytokines with their targets [11e13]. Carbohydrates are
also involved in chemotaxis of granulocytes. This is exempliﬁed by
N-acetylated-hexosamines, as they potentiate neutrophil recog-
nition and phagocytosis of polyglutaraldehyde microspheres
when covalently bound [14]. Mononuclear agranulocytes are also
considerably inﬂuenced by carbohydrate moieties, as macro-
phages possess carbohydrate-binding sites related to recognition,
binding, and processing of target molecules and cells. Even the
humoral immune response is markedly characterized by carbo-
hydrate dependence, as T-lymphocytes have lectin-like carbohy-
drate receptors that have been shown to affect antigen-speciﬁc
in vitro assays [14,15].
We have previously shown that halo carbonyls with antineo-
plastic activity in vivo (including haloacetamides) act as non-
charged lipophilic or amphiphilic electrophiles [14e16]. Further,
the compounds with the most antitumor activity in these series are
strong alkylating agents, and react by SN2 mechanisms, enabling a
concerted reaction to occur in lipophilic environments (such as the
plasma membrane). Since antitumor activity is dependent on the
polarity and alkylating activity of halo carbonyls, it has been
postulated that these analogs exert their effects by alkylating cell
surface nucleophiles in addition to intracellular nucleophiles (such
as DNA or proteins not found at the plasma membrane). Due to the
potential importance a carbohydrate moiety could have in devel-
oping novel alkylating agents with plasma membrane activity, and
to improve the speciﬁcity of haloacetamides, we have synthesized
novel tetra-O-acetate haloacetamido carbohydrate analogs (Tet-
OAHCs). These compounds have the R group substituted with car-
bohydrate derivatives found on the plasma membrane (Fig. 1), and
appear to have high alkylating activity, marked antitumor activity
in vivo against solid tumors and disseminated cancers [14,15,17],
and may potentiate host leukocyte inﬂux at the site of adminis-
tration and tumor challenge [17]. Acetylation of carbohydrate hy-
droxyl groups has proven to be necessary, as attaching a
hydrophilic moiety to a haloacetamide signiﬁcantly reduces anti-
tumor activity, as observed by haloacetamides with free sugars
[14,15].
In regards to potentiating leukocyte inﬂux, we have shown that
when N-bromoacetyl-b-D-glucosamine tetra-O-acetate produced
long term survival in mice challenged with Ehrlich ascites murine
carcinoma after a single injection (0.11 mmol/kg), it was observed
that the sites of tumor challenge and drug administration had a
rapid granulocyte inﬂux [17]. Further, N-bromoacetyl-b-D-galac-
tosamine tetra-O-acetate injected i.p. at the same dose one dayprior to a challenge of 1  106 Ehrlich ascites carcinoma cells
conferred substantial resistance to lethal tumor outgrowth when
compared to vehicle-treated control animals. Although potential
plasma membrane alkylating chlorohydroxyacetone-benzoate de-
rivatives were shown to produce some long term survival in the
same tumor system [18], they were not associated with an
increased granulocyte inﬂux, nor did pretreatment of such com-
pounds one day prior to tumor challenge confer any noticeable
resistance.
Although our previous experimental data suggest that Tet-
OAHCs are potent alkylating agents capable of potentiating leuko-
cyte inﬂux, most of the data have been circumstantial. We have yet
to deﬁnitively conﬁrm the partition coefﬁcient and alkylating ac-
tivity of these congeners as we previously have with other halo
carbonyls, as well as demonstrate that the increased immune
response in vivo can be quantitatively attributed to the acetylated
carbohydrate moiety. Therefore, the present study intends to
further characterize the chemical attributes of the analogs by
evaluating their partition coefﬁcients and alkylating activities. In
addition, we will conﬁrm the in vitro antineoplastic activity of Tet-
OAHCs by assessing their cytotoxicity against Ehrlich ascites carci-
noma, as well as U937 human monocytic leukemia and L1210
murine lymphoid leukemia. In vivo antineoplastic activity will be
assessed by challenging large cohorts of B6D2F1 and CD2F1 mice
with a normally lethal i.p. injection of Ehrlich ascites carcinoma
cells, prior to being treated with a single dose of one of the analogs,
while also acquiring the ED50, LD50, and therapeutic indices of these
congeners. We also compare the ability of Tet-OAHCs to potentiate
long term survival in mice challenged with Ehrlich ascites carci-
noma with clinically approved agents (daunorubicin and mech-
lorethamine). Finally, a quantitative comparison of host leukocyte
inﬂux between Tet-OAHCs and another lipophilic monofunctional
non-carbohydrate alkylating agent that appears to have activity
toward the plasma membrane, bromohydroxyacetone benzoate
(BrHAB), will be performed to conﬁrm previous in vivo observations
that the tetra-O-acetate carbohydrate moiety is important for
inducing a host leukocyte response in murine models.2. Materials and methods
2.1. Preparation of neoplastic cell lines
Ehrlich ascites murine carcinoma (ATCC® CCL-77), L1210murine
lymphoid leukemia (ATCC® CCL-219), and U937 human monocytic
leukemia (ATCC® CRL-1593.2) were acquired commercially. Ehrlich
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ﬂasks and suspended in NCTC 135medium supplemented with 10%
fetal bovine serum. Suspension leukemia cell lines were seeded at
similar concentrations (5.2  104 cells/ml) in 75 cm2 ﬂasks, but
were suspended in 20% fetal bovine serum (FBS) in Iscove's me-
dium without glutamine, with the following added: 200 units/ml
penicillin, 200 mg/ml streptomycin, 100 mg/ml gentamicin sulfate,
40 mM glutamine (50 ml of 2 mM glutamine per 5 ml medium), and
50 ml of amphotericin B (2.5 mg/ml concentration) per 5 ml of me-
dium. Flasks were incubated in 5% CO2 at 37 C. Once conﬂuent,
Ehrlich ascites carcinoma cells were trypsinizedwith 0.05% trypsin-
EDTA solution 1X (SigmaeAldrich Corp., St. Louis, MO, USA) for
5 min at 37 C, dislodged by a sharp knocking of the ﬂasks during
that period, washed, diluted to 10 ml with fresh complete medium,
and cells were seeded into 75 cm2 culture ﬂasks at a 1:3 sub-
cultivation ratio.
A Z2 BeckmaneCoulter® Particle Count and Size Analyzer
(Beckman Coulter Inc., Brea, CA, USA) along with a Bio-Rad® TC20
Automated Cell Counter (Bio-Rad Laboratories, Inc., Hercules, CA,
USA) were used to assess the inhibitory effects of the four Tet-
OAHCs. Cell viability was determined with trypan blue staining
and analysis with the TC20 cell counter. In addition, cell viability
was assessed with a XTT Cell Proliferation Assay Kit (ATCC®
30e1011K). 100 ml of cells were seeded per well into a ﬂat-bottom
96-well microtiter plate in triplicate for each cell dilution. The plate
was incubated for 24 h prior to addition of XTT solution. Cells were
then incubated for an additional 2 h before the wavelength was
read.
2.2. Syntheses of tetra-O-acetate haloacetamido carbohydrate
analogs
The molecular structures of all four 2-deoxy-2-
bromoacetamido-D-hexose 1,3,4,6 tetra-O-acetates examined in
the present study, N-bromoacetyl-a-D-glucosamine tetra-O-acetate
(Br-Tet-O-a-glucosamine), N-bromoacetyl-b-D-glucosamine tetra-
O-acetate (Br-Tet-O-b-glucosamine), N-bromoacetyl-b-D-galactos-
amine tetra-O-acetate, (Br-Tet-O-b-galactosamine), and N-bro-
moacetyl-a-D-mannosamine tetra-O-acetate (Br-Tet-O-a-
mannosamine), are presented in Fig. 2A, and were synthesized as
previously described [14,15,17]. Bromoacetamido analogs were
synthesized as these congeners have demonstrated more anti-
neoplastic activity than other halogen acetamido analogs we have
investigated [15]. Simple haloacetamides, haloacetates, and non-
hexose haloacetamido derivatives examined in the present study
were acquired commercially (SigmaeAldrich Corp.), or were syn-
thesized from derivatives similar in structure.
2.3. Assessing the partition coefﬁcients and alkylating activities of
tetra-O-acetate haloacetamido carbohydrate analogs
The partition coefﬁcient between n-octanol and water was
determined by A240 measurement of solutions of the various
compounds in either n-octanol or water prior to extraction, and in
both phases after extraction. This method has been checked using
compounds of known log P, by high performance liquid chroma-
tography, thin layer chromatography, and by organic halide anal-
ysis. Analogs with log P values ranging from2 toþ2were denoted
as having an intermediate partition coefﬁcient. Alkylating activity
at 37 C in aqueous conditions, pH 7.1, was determined by an assay
that used the initial pseudo-ﬁrst-order rate constant of halide loss
in the presence of 5% pyridine-acetate (Fig. 2B). This was done to
determine alkylating activity as a function of the dielectric constant
of the solvent medium. In addition, this assay can be used to
monitor the rate of alkylation in different solvent media, which willbe important in future attempts to design membrane-directed
agents that affect electron donors in a medium of low polarity, as
is the case with the plasma membrane. Alkylating activity was
assessed by determining the mM X loss/min/mM RX for each
compound. Values were in accordance to those acquired by the
Friedman and Boger SN2 nucleophilic substitution method using p-
nitrobenzylpyridine in a solvent of 83% acetone with 0.1 M inor-
ganic phosphate (Pi), pH 7.2 and temperature at 37 C [19].
2.4. Ehrlich ascites murine carcinoma in vivo
B6D2F1 and CD2F1mice were challenged with a normally lethal
i.p. injection of 2.5  107 Ehrlich ascites carcinoma cells, prior to
being treated with one of the analogs. The 2.5 107 cell injection of
Ehrlich ascites carcinoma is ten times the minimum dose lethal to
95% of B6D2F1 mice [17], and produced a median survival of 16
days when mice were treated only with the vehicle or left
untreated.
2.5. Formulation of tetra-O-acetate haloacetamido carbohydrate
analogs for assessing In vivo antineoplastic activity
Br-Tet-O-a-glucosamine, Br-Tet-O-b-glucosamine, Br-Tet-O-b-
galactosamine, and Br-Tet-O-a-mannosamine were suspended in
10% tween 80 made up to 0.85% NaCl solution. The agents were
then administered as single i.p. injections.
2.6. Assessing the leukocyte inﬂux in B6D2F1 mice following
administration of tetra-O-acetate haloacetamido carbohydrate
analogs
B6D2F1micewere administered a single ED50 dose i.p. of Br-Tet-
O-b-glucosamine or Br-Tet-O-b-galactosamine (ED50 against
2.5  107 Ehrlich ascites carcinoma cells injected i.p. 24 h prior to
administration of the analogs). 8 mice served as background con-
trols for peritoneal cells in B6D2F1 mice. Untreated controls were
sacriﬁced one day prior to drug administration in the other treat-
ment groups. All mice had their total peritoneal contents recovered,
counted, and analyzed with Wright-Giemsa stain.
3. Results
3.1. In vitro efﬁcacy of tetra-O-acetate haloacetamido carbohydrate
analogs
Tet-OAHCs appeared to have similar activity against suspension
cell lines (U937 and L1210) and the adherent Ehrlich ascites carci-
noma cells, with comparable IC50 values being attained after
treatment for 48 h (Fig. 3). Two exceptions were the increased
cytotoxicity Br-Tet-O-a-glucosamine had towards U937 (2.10 mM),
and the slight, but noticeably decreased cytotoxicity of Br-Tet-O-a-
mannosamine against all cell lines.
3.2. Efﬁcacy of tetra-O-acetate haloacetamido carbohydrate
analogs on potentiating long term survival in Ehrlich ascites murine
carcinoma
All four Tet-OAHCs appeared to potentiate long term survival to
at least 60 days when administered as a single i.p. injection in both
B6D2F1 and CD2F1mice challenged i.p. with a normally lethal dose
of 2.5  107 Ehrlich ascites carcinoma cells (Table 1). While mice
treated only with the vehicle lived for a median of 16 days, CD2F1
mice treated with Br-Tet-O-b-glucosamine reached 60 day survival
at a rate of 96.4% (27/28 mice), with successful treatment requiring
as little as 0.07 mmol/kg. Similar results were attained in the
Fig. 2. Molecular structures of 2-deoxy-2-bromoacetamido-D-hexose 1,3,4,6 tetra-O-acetates, and the assay used to determine their alkylating activity. A) Four Tet-OAHCs were
examined in the present study. Abbreviations of the compounds used are given underneath the formal name. B) Assay used to determine alkylating activity of Tet-OAHCs.
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glucosamine (ranging from 0.09 to 0.15 mmol/kg), as these mice
were alive 60 days after the initial tumor challenge at a rate of 91.9%
(34/37 mice). Br-Tet-O-b-galactosamine also exhibited marked
antitumor activity, with 62.5% (5/8 mice) CD2F1 mice surviving to
at least 60 days when treated with a single dose ranging from 0.05
to 0.08 mmol/kg, and 81.8% (166/203 mice) B6D2F1 mice surviving
the same length of time when treated with 0.06e0.15 mmol/kg. Br-
Tet-O-a-mannosamine was only examined in CD2F1 mice, but eli-
cited a 90% (18/20 mice) survival rate 60 days after the initial tumor
challenge when administered at 0.13e0.29 mmol/kg
0.045e0.11 mmol/kg. Br-Tet-O-a-glucosamine potentiated long
term survival at 58.3% (7/12 mice), with three of those deaths
possibly attributed to drug toxicity, as the LD50 of the tetra-O-
acetate derivative of Br-Tet-O-a-glucosamine is 0.11 mmol/kg
(three mice received the LD50 in this cohort). Nevertheless, all Tet-
OAHCs examined potentiated long term survival at a much higher
rate than daunorubicin, including when the anthracycline was
administered on two consecutive days (4/20 mice), rather than a
single day (0/10 mice; Table 1).Interestingly, it appears that the functional group used to make
the carbohydrate more lipophilic has a profound inﬂuence on
antineoplastic activity as a tetra-O-propionate derivative of b-
glucosamine did not produce any long term survival in CD2F1 mice
at 60 days (0/8 mice), even when administered at a higher con-
centration (0.75 mmol/kg) in comparison to the other bromoace-
tamido-D-hexose analogs (Table 1). In addition, it appears that the
Tet-OAHCs have similar ED50 values (0.04 mmol/kg to 0.12 mmol/
kg), but variable LD50values (0.11 mmol/kg to 0.41 mmol/kg), pro-
ducing therapeutic indices ranging from 2.8 (Br-Tet-O-a-glucos-
amine and Br-Tet-O-a-mannosamine in CD2F1 mice) to 5.2 (Br-Tet-
O-b-glucosamine in CD2F1 mice).
3.3. Efﬁcacy of simple haloacetamides, haloacetates, and non-
hexose haloacetamido derivatives in CD2F1 Ehrlich ascites tumor-
bearing mice
Tet-OAHCs appear to have potent antineoplastic activity in vivo
against Ehrlich ascites carcinoma not observed in other hal-
oacetamides and haloacetates (Table 2). While Tet-OAHCs could
Fig. 3. 50% inhibitory concentrations of 2-deoxy-2-bromoacetamido-D-hexose 1,3,4,6 tetra-O-acetates at 48 h against U937 human monocytic leukemia, L1210 murine lymphoid
leukemia, and Ehrlich ascites murine carcinoma. IC50 values were assessed with two separate cell counters and trypan blue exclusion, as well as with an XTT kit. Bars represent
standard error of the mean (SEM) of 4 individual Tet-OAHC treatments for all cell lines. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
Table 1
Efﬁcacy of 2-deoxy-2-bromoacetamido-D-hexose 1,3,4,6 tetra-O-acetates and daunorubicin in ehrlich ascites tumor-bearing mice.
Agent Mice LD50/ED50 (mmol/kg) Survivors at 60 days (number/treated) Dose range (mmol/kg) Therapeutic Index
b-Glucosamine
Tetra-O-Acetate CDF 0.31/0.06 27/28 0.07e0.37 5.2
BDF a0.36/0.07 34/37 0.09e0.15 5.1
Tetra-O-Propionate CDF 0.89/NE 0/8 0.75 e
b-Galactosamine CDF 0.22/0.05 5/8 0.05e0.08 4.4
BDF 0.24/0.07 166/203 0.06e0.15 3.4
a-Mannosamine CDF a0.33/0.12 18/20 0.13e0.29 2.8
a-Glucosamine CDF a0.11/0.04 7/12 0.045e0.11 2.8
Daunorubicin CDF 5.78  103/NE 0/10 5.68  104 (1x)b e
4/20 5.68  104 (2x)b e
a LD50 values were found in tumor challenged mice. Other LD50 values were found in nontumor-bearing mice.
b Daunorubicin was administered on either day 1 only, or days 1 and 2, while the other agents were administered only on day 1. ED50 refers to a dose that elicited 50%
survivors at day 40. Therapeutic index ¼ LD50/ED50. Mice were given a single i.p. injection (other than daunorubicin 2x) of all agents one day after an i.p. tumor challenge of
2.5  107 Ehrlich ascites carcinoma cells. BDF refers to B6D2F1 mice, while CDF refers to CD2F1 mice. NE: not evaluated.
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at rates as high as 96.4%, haloacetamides and haloacetates not
conjugated to an acetylated carbohydrate hardly ever elicited such
a response. None of the 6 non-hexose haloacetamides examined
potentiated long term survival to 60 days, even when
ClCH2CONH2 was administered at 0.81 mmol/kg (LD50 ¼ 0.86 in
CD2F1 mice). While one of the halo acetates (BrCH2COO) pro-
duced a survival rate of 25% (4/16 mice) 60 days after the initial
tumor challenge, no other compound in Table 2 potentiated long
term survival at a rate higher than 8% (CH3C(CH2OH)2NHCOCH2Br;
2/25 mice), and most did not have any survivors at the 60 day
mark. Further, BrCH2COO had a therapeutic index of 1.06, and
requires too high of a concentration to elicit any sustainable
therapeutic beneﬁt.
3.4. Effects of partition coefﬁcient and alkylating activity on
antineoplastic activity of haloacetamides in CD2F1 mice challenged
with Ehrlich ascites murine carcinoma
It appears that both partition coefﬁcient and alkylating activity
have a substantial inﬂuence on the antineoplastic activity of hal-
oacetamides in Ehrlich ascites tumor-bearing CD2F1 mice (Table 3).Br-Tet-O-b-glucosamine, which potentiated a 96.4% survival rate at
60 days had alkylating activity ¼ 8.6  102 mM X loss/min/mM
RX,with an intermediate log P value of 0.23. In addition to Br-Tet-O-
b-glucosamine, the other active Tet-OAHCs had similar alkylating
activities and intermediate partition coefﬁcients. Interestingly,
while the tetra-O-propionate b-glucosamine bromoacetamide had
the highest alkylating activity (9.6  102 mM X loss/min/mM
RX), it did not produce any long term survival in CD2F1 mice
challenged with Ehrlich ascites carcinoma (Table 1). Interestingly,
this tetra-O-propionate derivative had a lipophilic log P value of
2.25, suggesting that increasing the lipophilicity of Tet-OAHCs
beyond an intermediate range might be detrimental to their efﬁ-
cacy. This is further supported by the non-carbohydrate bromoa-
cetamide 2-bromoacetamido-4-nitrophenol, which has an
alkylating activity higher than two of the active Tet-OAHCs
(7.7  102 mM X loss/min/mM RX), but is more lipophilic (log
P ¼ 1.78), and is less active against Ehrlich ascites carcinoma; this
compound was assessed for antineoplastic activity in Ehrlich asci-
tes tumor-bearing mice in Ref. [17]. We have previously demon-
strated that the free sugar b-glucosamine bromoacetamide has
considerably reduced antineoplastic activity [17], and this may now
also be attributed to its relatively low alkylating activity
Table 2
Activity levels of simple haloacetamides, haloacetates, and non-hexose haloacetamide derivatives in CD2F1 ehrlich ascites tumor-bearing mice.
Compound LD50/ED50 (mmol/kg) Survivors at 60 days (number/treated) Dose range (mmol/kg) Medium Life vs control (%) Therapeutic Index
Haloacetamides
ClCH2CONH2 0.86/NE 0/5 0.81 100 <1
BrCH2CONH2 0.24/NE 0/15 0.11e0.25 100 <1
ICH2CONH2 0.19/NE 0/5 0.15 100 <1
BrCH2CONHEt 0.52/NE 0/8 0.30e0.45 100 <1
BrCH2CONHnPr 0.62/NE 0/25 0.12e0.40 100 <1
BrCH2CONHnHex 0.36/NE 0/7 0.26 100 <1
Haloacetates
BrCH2COO 0.49/NE 4/16 0.30e0.65 100 <1
BrCH2COOMe 0.20/NE 0/5 0.15 100 <1
BrCH2COOEt 0.32/NE 0/28 0.17e0.37 100 <1
Derivatives of 2-Methyl-Amino 1,3 Propane Diol
CH3C(CH2OH)2NHCOCH2Br 0.18/0.17 2/25 0.04e0.15 107 1.06
Mono-O-Acetate 0.46/NE 1/15 0.17e0.37 121 <1
Di-O-Acetate 0.53/NE 0/15 0.11e0.26 117 <1
Derivative of Tris-Hydroxymethyl Amino-Methane
C(CH2OH)3NHCOCH2Br 0.22/NE 0/10 0.10e0.15 119 <1
Derivatives had alkylating activity and log P values spanning the range of active haloacetamido compounds. Derivatives of 2-methyl-amino 1,3 propane diol:
CH3C(CH2OH)2NHCOCH2Br (alkylating activity: 3.6, log P: 0.43); mono-O-acetate (alkylating activity: 4.5, log P:-0.07); di-O-acetate (alkylating activity: 5.7, log P: 0.90).
Derivative of tris-hydroxymethyl amino methane: C(CH2OH)3NHCOCH2Br (alkylating activity: 2.9, log P: 1.14). NE refers to ED50 values that were not evaluated.
Table 3
Effects of partition coefﬁcient and alkylating activity on antitumor activities of
haloacetamides in ehrlich ascites tumor-bearing CD2F1 mice.
Compounds Active Log P Alkylating Activity
N-Bromo-D-Hexosamines
b-Glucosamines: Tetra-O-Acetate Yes 0.23 8.6
Tetra-O-Propionate No 2.25 9.6
Free Sugar No 3.91 2.1
b-Galactosamine: Tetra-O-Acetate Yes 0.21 8.8
a-Mannosamine: Tetra-O-Acetate Yes 0.24 4.6
a-Glucosamine: Tetra-O-Acetate Yes 0.22 6.3
Other Bromine-Containing Compounds
2-Bromoacetamido-4-Nitrophenol Weak 1.78 7.7
BrCH2CONHEt No 0.37 3.6
BrCH2CONHnPro No 0.91 3.6
BrCH2CONHnHex No 2.18 3.6
BrCH2CONH2 No 0.52 2.6
BrCH2COO No 1.95 3.4
BrCH2COOMe No 0.77 3.9
BrCH2COOEt No1.30 3.7
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drophilicity (log P ¼ 3.91).
Based on the potential relationship of alkylating activity and
partition coefﬁcient in regards to antineoplastic activity, structure-
activity plots were developed for Tet-OAHCs and other halo car-
bonyls (Fig. 4). From these analyses, it appears that alkylating ac-
tivity does not have a marked effect on host toxicity (p ¼ 0.22), but
that increasing log P values appear to reduce toxicity (p ¼ 0.0004).
The potential importance of these ﬁndings will be elaborated upon
in the discussion.3.5. Extent of leukocyte inﬂux in B6D2F1 mice following
administration of tetra-O-acetate haloacetamido carbohydrate
analogs
A quantitative comparison of host leukocyte inﬂux between
Tet-OAHCs and another monofunctional non-carbohydrate alky-
lating agent (BrHAB) is shown in Fig. 5. Panel A indicates that only
the carbohydrate analogs, and to a lesser extent BrHAB, produced
a further increase in non-basophilic granulocytes 24 h post-
administration, whereas the early response induced by other
agents subsided by this time. The elevated granulocyte levels were
still observed in the carbohydrate analog groups 48 h post-drugadministration. Panels B and C demonstrate that neutrophils
were responsible for the granulocyte early response, while eo-
sinophils induced the persisting response.While the carbohydrate
analogs had both neutrophil and eosinophil inﬂux, BrHAB only
induced neutrophil inﬂux, corresponding to reduced granulocyte
inﬂux levels at the 24 h period. Panel D indicates that monocyte
inﬂux was preferentially stimulated in groups A and B (Br-Tet-O-
b-glucosamine and Br-Tet-O-b-galactosamine, respectively), and
that this effect was still increasing at 72 h post-drug administra-
tion. Panel E demonstrates that while the Tet-OAHCs reduced
lymphocyte counts immediately after administration, the counts
recovered by 72 h post-drug administration. Panel F presents the
total cell counts which correspond to the early reduction in
lymphocyte counts, and following lymphocyte recovery, are
inﬂuenced by granulocyte and monocyte-macrophage inﬂux.3.6. Long term survival of Ehrlich ascites tumor-bearing B6D2F1
and CD2F1 mice by pretreatment with tetra-O-acetate
haloacetamido carbohydrate analogs
We have previously observed that apparent cures of preexisting
Ehrlich tumors in mice with Tet-OAHCs are associated with the
elevated inﬂux of host granulocytes that is not observed with
ineffective agents [17]. Based on the leukocyte inﬂux potentiated by
Tet-OAHCs Br-Tet-O-b-glucosamine and Br-Tet-O-b-galactosamine,
it is possible that these congeners are exerting antitumor effects
in vivo in part by altering host response at the tumor site. In order to
further examine the importance of carbohydrate speciﬁcity in
eliciting therapeutic beneﬁts, Br-Tet-O-b-glucosamine, Br-Tet-O-b-
galactosamine, a monfunctional alkylating agent (BrHAB), and a
difunctional alkylating agent (mechlorethamine) were adminis-
tered as a single i.p. dose 24 h prior to B6D2F1 and CD2F1 mice
being challengedwith 1, 2, or 5 106 Ehrlich ascites carcinoma cells
(Table 4). While pretreatment of both B6D2F1 and CD2F1micewith
either Br-Tet-O-b-glucosamine or Br-Tet-O-b-galactosamine
consistently potentiated long term survival at day 60 for each
concentration of tumor challenge, these potent antineoplastic ef-
fects were not observed with BrHAB or mechlorethamine. Such
ﬁndings indicate that alkylating activity alone is not responsible for
the consistent long term survival elicited by pretreating mice with
Tet-OAHCs, and that immunopotentiation may be an important
component of their antitumor effects in mice challenged with
Fig. 4. Structure-activity plots of alkylating activity and partition coefﬁcient vs. host toxicity for tetra-O-acetate haloacetamido carbohydrate analogs and other halo carbonyls. A)
Alkylating activity vs. LD50 in CD2F1 mice. Correlation coefﬁcients: þ 0.24 for all 19 compounds; þ 0.35 for the 15 non-aromatic haloacetamido derivatives (p ¼ 0.22 for compounds
a through z, excluding s). B) Log P vs. LD50 in CD2F1 mice. Correlation coefﬁcients: þ 0.38 for all 18 compounds (p ¼ 0.12); þ0.82 for the 14 non-aromatic haloacetamido derivatives
(p ¼ 0.0004 for compounds a through z, excluding s). Important abbreviations used are as follows: Galm (galactosamine), Gm (glucosamine), Mm (mannosamine), Pro (propionate)
and TA (tetra-O-acetate).
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4. Discussion
Tet-OAHCs are novel alkylating agents with intermediate
partition coefﬁcients that appear to have in vitro activity against
suspension (U937 and L1210), and adherent (Ehrlich ascites carci-
noma) neoplastic cell lines, as well as potent in vivo antineoplastic
activity against Ehrlich ascites carcinoma. In vitro, Tet-OAHCs had
comparable cytotoxicities against the U937 and L1210 leukemias, as
well as Ehrlich ascites carcinoma (Fig. 3). In vivo, all four analogs
consistently produced long term survival to at least 60 days in
B6D2F1 and CD2F1micewhen administered as single i.p. injections24 h after a tumor challenge that typically kills mice in 16 days
(Table 1). The high antineoplastic activity these agents demon-
strated against Ehrlich ascites carcinoma in vivowas highlighted by
Br-Tet-O-b-glucosamine, which produced a 96.4% survival rate in
CD2F1 mice, and a 91.9% survival rate in B6D2F1 mice. This dra-
matic antitumor activity is observed in concentrations well below
the LD50, suggesting that therapeutic levels of the congeners can be
safely administered in mice as a single i.p. dose.
The therapeutic indices of Tet-OAHCs in the present study
ranged from 2.8 to 5.2, indicative of a narrow, but feasible thera-
peutic window for Ehrlich ascites tumor-bearing murine models.
By contrast, simple haloacetamides, haloacetates, and non-hexose
haloacetamides did not potentiate any notable long term survival
Fig. 5. Effects of tetra-O-acetate haloacetamido carbohydrate analogs on host leukocyte inﬂux. Groups A, B, and C received i.p. injections of 0.065 mmol/kg of the respective
compound (see legend above graphs), corresponding to their approximate single ED50 doses against 2.5  107 Ehrlich tumor cells given 24 h prior to drug administration. Group D
received 0.065 mmol/kg i.p. of NBrAcGm (the free sugar derivative of the corresponding carbohydrate analog, group A of the treatment schedules), while group E received the same
dosage of glucosamine penta-acetate. Group V was the vehicle controls, and group U served as background controls for peritoneal cells in BD2F1 mice. Total peritoneal contents
were recovered, counted and Wright-Giemsa stained. Animals in groups A-V were sacriﬁced in groups of four at 4, 24, 48, and 72 h post-drug administration. Each treatment group
had 16 mice included, except for group U (background controls) in which only 8 were used. Abbreviations used are as follows: b-NBrAcGm-TA (Br-Tet-O-b-glucosamine), b-
NBrAcGalm-TA (Br-Tet-O-b-galactosamine), BrHAB (bromohydroxyacetone benzoate), and NBrAcGm (free sugar b-glucosamine bromoacetamide). Bars represent SEM of each
population.
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demonstrated alkylating activity (Table 3). Further, in the present,
as well as in a previous study [17], we have shown that propionate
haloacetamido carbohydrate derivatives do not elicit marked
antitumor activity (Table 1). Nevertheless, the alkylation assay
revealed that the propionate bromoacetamido b-glucosaminederivative had the highest alkylating activity of all the tested hal-
oacetamides (9.6  102 mM X loss/min/mM RX), suggesting that
the potent antineoplastic activity of Tet-OAHCs in Ehrlich ascites
tumor-bearing mice resides in more than alkylating activity alone.
This notion is further validated by Br-Tet-O-a-mannosamine, which
had a lower alkylating activity than the other active carbohydrate
Table 4
Efﬁcacy of pretreating B6D2F1 and CD2F1 mice challenged i.p. with ehrlich ascites murine carcinoma with 2-deoxy-2-bromoacetamido-D-hexose 1,3,4,6 tetra-O-acetates, or
with non-carbohydrate monofunctional and difunctional alkylating agents 24 h prior to challenge.
Agent I.P. Dose
(mmol/kg)
Relationship to LD50
(mmol/kg)
B6D2F1 60 Day survivors I.P. Cell challenge ( 106) CD2F1 60 Day survivors 1  106 cell I.P.
Challenge
1.0 2.0 5.0
b-Glucosamine 0.11 0.27e0.31 16/16 8/8 5/7 14/15
b-Galactosamine 0.11 0.42e0.46 16/16 8/8 8/8 16/16
BrHAB 0.12 0.40e0.50 5/15 1/8 0/7 2/15
Mechlorethamine 0.10 0.45 3/16 e e 0/16
Tween-Salinea e e 0/16 e e 0/8
a Vehicle used to deliver agents.
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tive, and 2-bromoacetamido-4-nitrophenol, but still potentiated
long term survival in nearly all CD2F1 mice challenged with Ehrlich
ascites carcinoma (18/20 mice; Table 1). The lower alkylating ac-
tivity (Table 3), and potentially the lower in vitrocytotoxicity of Br-
Tet-O-a-mannosamine against the three neoplastic cell lines
examined (Fig. 3) in comparison to its congeners may be attributed
to its unique stereochemistry and subsequent steric effects. The
mannose carbohydrate moiety likely positions the bromoaceta-
mido group in an axial position, as opposed to the other three Tet-
OAHCs that have the bromoacetamido group in an equatorial po-
sition (Fig. 2A).
In addition to being potent electrophiles, it appears that Tet-
OAHCs may also act as immunopotentiating agents in both
B6D2F1 and CD2F1 mice. While the monofunctional alkylating
agent BrHAB had a small, but notable increase in non-basophilic
granulocytes 24 h post-administration, BrHAB only induced
neutrophil inﬂux, corresponding to reduced granulocyte inﬂux
levels at the 24 h period (Fig. 5). By contrast, Br-Tet-O-b-glucos-
amine and Br-Tet-O-b-galactosamine had both neutrophil and
eosinophil inﬂux increase during this period, with the effects
lasting in excess of 48 h after the i.p. injection. In addition, mono-
cyte inﬂux was preferentially stimulated by Br-Tet-O-b-glucos-
amine and Br-Tet-O-b-galactosamine, with increases still being
observed at 72 h post-drug administration (Fig. 5D). While it is true
that the two congeners temporarily inhibited lymphocyte inﬂux
(Fig. 5E), this effect completely dissipated by 72 h, and Tet-OAHCs
had the highest overall leukocyte inﬂux by a relatively largemargin.
The potential importance of immunopotentiation in the anti-
tumor effects elicited by Tet-OAHCs was further observed when
two of the congeners (Br-Tet-O-b-glucosamine and Br-Tet-O-b-
galactosamine) were administered i.p. 24 h prior to Ehrlich ascites
tumor challenge (Table 4). While neither the monofunctional
(BrHAB) or difunctional (mechlorethamine) non-carbohydrate
alkylating agent potentiated signiﬁcant antitumor activity when
administered 24 h prior to the challenge, both of the Tet-OAHCs
produced extremely high survival rates at 60 days, with all of the
B6D2F1 and CD2F1 mice surviving this observation period after
being treated with a single i.p. injection of Br-Tet-O-b-galactos-
amine. This inherent survival difference potentiated by the twoTet-
OAHCs and the other alkylating agents again suggest that the
antineoplastic activity Tet-OAHCs demonstrate against Ehrlich as-
cites carcinoma is due to more than potent alkylating activity at the
cell surface, or with important intracellular nucleophiles. Due to
the observation that Tet-OAHCs potentiate leukocyte inﬂux at the
site of administration, as well as the tumor site, it appears that
immunopotentiation is at least partially responsible for the marked
antitumor activity elicited by the congeners. However, these in vivo
effects need to be conﬁrmed in other neoplastic cell lines to
deﬁnitively assess whether Tet-OAHCs potentiate immunothera-
peutic beneﬁts in addition to SN2 alkylating activity.
Analyses of the alkylating activities and partition coefﬁcients ofTet-OAHCs as well as other halo carbonyls revealed important
characteristics regarding the optimization of these agents.
Although the propionate derivate of bromoacetamido b-glucos-
amine exhibited the highest alkylating activity and log P value
(Table 3), it did not produce any long term survivors in CD2F1 mice
challenged with Ehrlich ascites carcinoma (0/8 mice; Table 1). This
is particularly striking, as the propionate derivate of bromoaceta-
mido b-glucosamine had the highest LD50 value of any of the an-
alogs (Table 1), andwas administered at higher concentrations than
other bromoacetamido carbohydrates. These effects were further
characterized in structure-activity plots (Fig. 4) that compared
alkylating activity and log P values to LD50 values in CD2F1 mice.
Since the active carbohydrate analogs in this series appear to have
relatively high alkylating activities and intermediate partition co-
efﬁcients, these correlations suggest that optimal haloacetamido
carbohydrates should have log P values in the range of 0.5e1, and
alkylating activity near or perhaps greater than 9  102 mM X
loss/min/mM RX. Haloacetamido carbohydrate analogs that should
adhere to both principles are proposed in Fig. 6. In addition to
monofunctional haloacetamido carbohydrates, difunctional hal-
oacetamido carbohydrates compounds are also posited as a means
to potentially increase alkylation rates. It is also well known that
difunctional alkylating agents have the propensity to crosslink
adjacent nucleophiles [2], and in theory should give haloacetamido
carrbohydrates another mechanism bywhich to damage neoplastic
cells. In addition, difunctional haloacetamido carbohydrates are
proposed because the present study does not preclude the poten-
tial afﬁnity these agents may have for DNA, as is observed with
traditional alkylating agents.
As with other novel antineoplastic agents, Tet-OAHCs will need
to be used in combinationwith clinically approved agents to reduce
the likelihood of drug resistance, and to improve their overall ef-
ﬁcacy. Interestingly, anthracyclines have a marked inﬂuence at the
cell surface. Anthracyclines are most commonly known as nucleic
acid-directed agents, as the compounds intercalate base pairs,
produce free radicals, and potently inhibit DNA topoisomerase II
function [2]. However, it has also been well established that
anthracyclines (particularly doxorubicin) alter the ﬂuidity of
neoplastic cell plasma membranes [20,21], and bind phospholipids
with considerably afﬁnity [22,23]. Some studies have also indicated
that extracellular doxorubicin is important for anticancer activity
and that the compound demonstrates marked cytotoxicity without
entering the cell [2,24]. Therefore, it may be possible to combine
anthracyclines with Tet-OAHCs to elicit potent drug synergy at the
cell surface or inside the nucleus. This possibility is made even
more intriguing by the fact that daunorubicin was much less
effective against Ehrlich ascites carcinoma than the Tet-OAHCs
examined in the present study (Table 1), and increasing the
in vitro and in vivo efﬁcacy of anthracyclines in multiple cancer
types using haloacetamido carbohydrates and anthracyclines in
combination could eventually warrant clinical investigation.
Acetylated haloacetamido carbohydrates are a particularly
Fig. 6. Proposed acetylated haloacetamido carbohydrate analogs with high alkylating activity and intermediate partition coefﬁcients for preclinical evaluation. Monofunctional
derivatives are as follows: I) N-bromoacetyl-galactosylamine-2,3,4,6-tetra-O-acetate, II) 1-O-bromoacetyl-glucose-2,3,4,6-tetra-O-acetate, III) N-bromoacetyl-fucosylamine-2,3,4-
tri-O-acetate, and IV) 6-deoxy-N-bromoacetyl-galactosamine-1,3,4-tri-O-acetate. Difunctional derivatives are as follows: V) 1,2-di-O-bromoacetyl-b-D-galactose-3,4,6-tri-O-ace-
tate, VI) 1,6-di-O-bromoacetyl-a or b-D-galactose-2,3,4-tri-O-acetate, VII) 2,6-di-N-bromoacetyl-2,6-dideoxy-2,6-diamino-galactose-1,3,4-tri-O-acetate, and VIII) 2,6-di-N-bro-
moacetyl-2,6-dideoxy-2,6-diamino-b-D-glucose-1,3,4-tri-O-acetate.
M. Trendowski et al. / European Journal of Medicinal Chemistry 98 (2015) 149e159158interesting group of alkylating agents, as they appear to potentiate
a substantial leukocyte inﬂux at the administration and primary
tumor site, indicative of possible immunopotentiation. This is a
particularly important observation, as traditional DNA-directed
alkylating agents are noted for inducing marked neutropenia in
the clinical setting [2,25,26]. An antineoplastic agent that promotes
leukocyte inﬂux could be a particularly beneﬁcial supplement to
many current chemotherapeutic protocols, and warrants further
in vivo examination of these novel congeners.
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